Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Janerich

Physical Medicine & Rehabilitation West Pittston, PA Doctor of Osteopathy

NPI 1932589843 CMS profile 2791844

901 Wyoming Ave, West Pittston, PA 18643

Open in the dashboard

General payments

$5,676

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Janerich of West Pittston, PA is reported in the CMS Open Payments database as having received $5,676 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,179 56
2024 General $1,683 72
2023 General $660 27
2022 General $766 37
2021 General $976 58
2020 General $208 7
2019 General $205 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Janerich
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to David Janerich were reported at $1,179. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year David Janerich Physical Medicine & Rehabilitation median Middle half National median
2019 $205 $133 $45–$390 $163
2020 $208 $88 $29–$272 $114
2021 $976 $116 $33–$360 $132
2022 $766 $123 $40–$378 $149
2023 $660 $131 $43–$396 $160
2024 $1,683 $141 $45–$409 $164
2025 $1,179 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,742 75 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $702 42 payments
  3. Collegium Pharmaceutical, Inc. $453 31 payments
  4. Ipsen Biopharmaceuticals, Inc $286 15 payments
  5. Globus Medical, Inc. $259 7 payments
  6. Nevro Corp. $245 11 payments
  7. Abbott Laboratories $231 4 payments
  8. SI-BONE, Inc. $229 5 payments
  9. Biodelivery Sciences International, Inc. $149 10 payments
  10. AbbVie, Inc. $135 7 payments
  11. Other $1,246 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,237 261 payments
  2. Travel and Lodging $306 1 payment
  3. Education $132 1 payment
Products named General payments · program years 2019–2025
  1. RELISTOR Gastroenterology $427 27 payments
  2. General - Pain Management $413 11 payments
  3. XTAMPZA $323 24 payments
  4. WaveWriter Alpha Prime 16 $305 8 payments
  5. DYSPORT $286 15 payments
  6. RELISTOR Gastroenterology $275 15 payments
  7. Senza Spinal Cord Stimulator $259 7 payments
  8. Senza Spinal Cord Stimulator $245 11 payments
  9. Infinion 16 $201 37 payments
  10. BELBUCA $149 10 payments
  11. Other $2,139 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

220

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$194,358

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

45%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 84 $167,388
Dysport Abobotulinumtoxina Brand 15 $25,746
Gabapentin Generic 38 $487
Tizanidine Hcl Generic 19 $175
Pregabalin Generic 19 $163
Cyclobenzaprine Hcl Generic 14 $141
Diclofenac Sodium Generic 11 $132
Celecoxib Generic 20 $126

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$172,579

Of which drugs: $515

Medicare patients

262

Average age 73

Services billed

2,601

158 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Ischemic heart disease 28%
Depression 26%
Chronic kidney disease 24%
Osteoporosis 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 13 245 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $157
$157 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $123
$123 15 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $58
$58 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $58
$58 — —
BOTOX
  • AbbVie, Inc. $38
$38 84 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record